Nyrada (ASX:NYR) said it submitted a human research ethics committee application for its phase IIa clinical trial of its Xolatryp drug candidate in patients with ST-elevation myocardial infarction undergoing a percutaneous coronary intervention treatment, according to a Tuesday Australian bourse filing.

The percutaneous coronary intervention treatment is associated with myocardial ischemia reperfusion injury that occurs when blood flow is restored to the heart after the ST-elevation myocardial infarction, a severe form of a heart attack.

The randomized, double-blind, placebo-controlled, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Xolatryp in male and female patients with ST-elevated myocardial infarction who are undergoing primary percutaneous coronary intervention. Around 200 patients are expected to be dosed during the trial.

The trial is on track to commence with patient dosing in March 2026, and the committee's final decision is expected in February 2026. Accelagen was engaged as the contract research organization for the trial.

The firm's shares fell 11% in recent trading on Tuesday.